

## **Roquette Expands PEARLITOL® SD Mannitol Range for Highly Sensitive Active Pharmaceutical Ingredients (APIs)**

**GENEVA, Illinois (Tuesday, July 5<sup>th</sup>) – Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical excipients, today announces the addition of a new grade to its PEARLITOL® SD mannitol range for direct compression – PEARLITOL® 150 SD. Developed specifically for active pharmaceutical ingredients (APIs) that are highly sensitive to reducing sugars, PEARLITOL® 150 SD supports opportunities to unlock advanced tablet dosage forms – even when using challenging active ingredients.**

Roquette's spray-dried PEARLITOL® SD grades are considered a leading direct compression functional filler/diluent for oral dosage forms in both pharmaceutical and nutraceutical applications. Like PEARLITOL® 100 SD and 200 SD, the 150 SD grade enables the direct compression of tablets without compromising quality or performance. The key difference is that PEARLITOL® 150 SD is a specifically-designed mannitol for direct compression of highly sensitive APIs. It ensures low levels of reducing sugars – below 300 ppm – meaning that it does not affect the stability of reducing sugar-sensitive APIs. Specifically developed with a narrow and controlled particle size distribution, PEARLITOL® 150 SD delivers good processability and reliable dosing in every tablet.

*“Our PEARLITOL® SD excipients are the first choice for direct compression without compromise – even for the most challenging and unstable formulations,”* says Steve Amoussou-Guenou, Global Technical Developer, Roquette. *“This extension of our one-of-a-kind mannitol range highlights our continuous drive to evolve and offer tailored solutions to better support customers’ needs. We realized that developing a grade of PEARLITOL® with low levels of reducing sugars could help our customers overcome the challenge of working with sensitive APIs in direct compression applications. Launching PEARLITOL® 150 SD to the market, alongside the other grades in the PEARLITOL® SD portfolio, opens up even more possibilities for drug delivery innovation in the pharmaceutical space.”*

As well as offering distinct advantages, such as consistent quality, superior functionality and high stability, Roquette's PEARLITOL® SD range brings excellent organoleptic properties and cost savings to direct compression formulations. In addition, it is underpinned by Roquette's extensive expertise and technical know-how in solid oral dosage formulations, and 40 years of experience supplying industry-leading, plant-based excipients and raw materials. Plus, all PEARLITOL® SD mannitol is backed by Roquette's Quality by Design pledge, with usage-specific documentation to support qualification and registration processes.

For more information about PEARLITOL® 150 SD and how it unlocks innovation with sensitive APIs, visit [www.roquette.com](http://www.roquette.com).



**About Roquette: “Offering the best of nature”**

*Roquette is a family-owned global leader in plant-based ingredients, a pioneer of plant proteins and a leading provider of pharmaceutical excipients. Founded in 1933, the company currently operates in more than 100 countries, has a turnover of 3.9 billion euros, and employs more than 8,000 people worldwide.*

*Life and nature have been our sources of inspiration for decades. All our raw materials are of natural origin. From them, we enable a whole new plant protein cuisine; we offer pharmaceutical solutions that play a key role in medical treatments; and we develop innovative ingredients for food, nutrition and health markets. We truly unlock the potential of nature to improve, cure and save lives.*

*Thanks to a constant drive for innovation and a long-term vision, we are committed to improving the well-being of people all over the world. We put sustainable development at the heart of our concerns, while taking care of resources and territories. We are determined to create a better and healthier future for all generations.*

Discover more about Roquette on this [link](#).

**Media contacts**

Roquette Corporate  
Carole Petitjean  
[carole.petitjean@roquette.com](mailto:carole.petitjean@roquette.com)

Roquette Global Pharmaceutical Communications  
Emily Delommez  
[emily.delommez@roquette.com](mailto:emily.delommez@roquette.com)

BDB Agency  
[roquette@bdb.co.uk](mailto:roquette@bdb.co.uk)  
+44 161 925 4700